

Evonik makes five generations healthier with EUDRAGIT® coatings for targeted drug delivery

- Over 23,000 patents with EUDRAGIT® in 70 years
- More than 10,000 scientific publications containing EUDRAGIT®
- Rooted in history, innovation with EUDRAGIT® is increasing Evonik's share of system solutions

Essen, Germany. EUDRAGIT® polymers have been used as coatings to create more effective drugs for 70 years. Over the decades, the portfolio of methacrylate polymers has established itself as the industry standard with more than 23,000 patents and 10,000 scientific publications mentioning the EUDRAGIT® brand. Today, customers in over 80 countries use EUDRAGIT® polymers in their formulations for modified release.

With its long-standing experience in functional excipients, formulation and application services, Evonik provides EUDRAGIT® polymers as key ingredients in multi-component systems that are tailored to a unique and specific customer need. These system solutions are driving a transformation within Evonik's life sciences division, Nutrition & Care, which is leveraging its expertise in biosolutions to increase its share of system solutions to 70 percent by 2032.

“From baby boomers to generation alpha, we are proud to have been enabling pharmaceutical innovation with EUDRAGIT® from day one, improving health outcomes around the world,” said Thomas Riermeier, head of the Health Care business line at Evonik.

EUDRAGIT® is the industry's preferred portfolio of functional polymers for use with oral drug products. The breadth, versatility and history of EUDRAGIT®, combined with Evonik's range of drug delivery technologies, formulation and cGMP manufacturing services, provides pharmaceutical companies with unrivalled safety, supply security and functional reliability for their oral solid dosage forms.

March 14, 2024

Main press contact

Janusz Berger
Head of Market Communications
Health Care
Phone +49 6151 18-4984
janusz.berger@evonik.com

Alternative press contact

Dr. Jürgen Krauter
Head of Market Communications Evonik
Phone +49 6181 59-6847
juergen.krauter@evonik.com

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Maike Schuh, Thomas Wessel

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

“Nearly everyone you know will have come into contact with EUDRAGIT® at some point in their life,” said Paul Spencer, head of Drug Delivery & Products at Evonik. “With a growing and aging population, we look forward to continuing to innovate these polymers into next-generation solutions, such as the recently launched EUDRACAP® which is fast becoming a leading choice for enteric capsule protection.”

EUDRAGIT® polymers are polymethacrylates suitable for use in drug delivery applications. Since 1954, Evonik has developed more than 20 types of EUDRAGIT® polymers that are ideal for all solid oral dosage forms including multi-particulates, regular or matrix tablets and hard or soft-gel capsules. EUDRAGIT® polymers can be used individually or in combination to match virtually any target release profile including immediate, delayed and sustained release. They are also compatible with all relevant process technologies including hot melt extrusion and spray drying for solubility enhancement.

Evonik’s Health Care business line, which is part of the Nutrition and Care division of Evonik, is one of the world’s leading integrated CDMOs for complex oral and parenteral drug products that require advanced drug delivery solutions. It is also one of the world’s largest pharmaceutical suppliers of generic APIs, amino acids and cell culture ingredients, and a top CDMO for APIs and intermediates.

Further Information

Information about patents from PatentSight
Number of publications taken from EBSCO Discovery Service
Indexes which contains scientific publications from a wide range of publishers.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable

solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.